Sotorasib and Panitumumab Versus Investigator’s Choice for Subjects with KRAS p.G12C Mutation

People with Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation are asked to participate in a research study being conducted by White Plains Hospital.

You may be eligible to participate in this study if you:

• Are a male or female at least 18 years of age
• Have pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation
• Have received at least 1 prior line of therapy for metastatic disease.
• You must be willing to provide archived tumor tissue samples
• Have adequate hematologic and end-organ function
• Have the ability to take oral medications

You may NOT participate in this study if you:

• Have active brain metastases
• Have history or presence of hematological malignancies
• Have history of other malignancy within the past 3 years
• Have known immunodeficiency virus (HIV) infection, Hepatitis B, or C
• Are pregnant or breastfeeding

Contact Information
Hyemin Kim, Study Coordinator
Phone: (914) 849-7591